A signaling pathway AKTing up in schizophrenia.
The serine/threonine protein kinase AKT (also known as PKB) signaling pathway has been associated with several human diseases, including schizophrenia. Studies in preclinical models have demonstrated that impaired AKT signaling affects neuronal connectivity and neuromodulation and have identified AKT as a key signaling intermediary downstream of dopamine (DA) receptor 2 (DRD2), the best-established target of antipsychotic drugs. A study by Tan et al. in this issue of the JCI strengthens links among AKT signaling, DA transmission, and cognition in healthy individuals and offers potential avenues to explore in an effort to find more effective pharmacotherapies for schizophrenia and related disorders (see the related article beginning on page 2200).
Arguello
P Alexander
PA
Department of Neuroscience and Department of Physiology and Cellular Biophysics, Columbia University Medical Center, New York, New York 10032, USA.
Gogos
Joseph A
JA
D000483:Alleles; D002470:Cell Survival; D003071:Cognition; D005091:Exons; D005786:Gene Expression Regulation; D006801:Humans; D008954:Models, Biological; D008957:Models, Genetic; D009474:Neurons / Q000378:metabolism; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism*; D017448:Receptors, Dopamine D2 / Q000378:metabolism; D012306:Risk; D012559:Schizophrenia / Q000175:diagnosis* / Q000378:metabolism*; D015398:Signal Transduction
D017448:Receptors, Dopamine D2; D051057:Proto-Oncogene Proteins c-akt